Recursion Pharmaceuticals (RXRX) Cash & Equivalents (2020 - 2026)
Recursion Pharmaceuticals' (RXRX) quarterly Cash & Equivalents came in at $654.5 million in Q1 2026, up 30.78% YoY from $500.5 million in Q1 2025, and down 11.95% on a QoQ basis from $743.3 million in Q4 2025.
Recursion Pharmaceuticals (RXRX) Cash & Equivalents (2020 - 2026) Analysis & Trends
Recursion Pharmaceuticals (RXRX) has 7 years of Cash & Equivalents data on file, last reported at $654.5 million in Q1 2026.
- Quarterly Cash & Equivalents rose 30.78% year-over-year to $654.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $654.5 million (up 30.78% YoY) and the FY2025 annual result came in at $743.3 million, up 25.06% from the prior year.
- Cash & Equivalents slipped to $654.5 million in Q1 2026, from $743.3 million in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $743.3 million in Q4 2025 to a low of $296.3 million in Q1 2024.
- A 5-year average of $500.0 million and a median of $474.3 million in 2024 frame the typical range for Cash & Equivalents.
- Annual changes were most pronounced in 2022 — Cash & Equivalents jumped 137.23% — and 2024, when it sank 37.37%.
- Tracing RXRX's Cash & Equivalents over 5 years: stood at $549.9 million in 2022, then dropped by 28.79% to $391.6 million in 2023, then soared by 51.79% to $594.4 million in 2024, then climbed by 25.06% to $743.3 million in 2025, then retreated by 11.95% to $654.5 million in 2026.
- The last three Cash & Equivalents figures came in at $654.5 million (Q1 2026), $743.3 million (Q4 2025), and $659.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 3.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 815.44 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.37 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 811.99 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.71 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 544.80 Mn |
| 10 | Recursion Pharmaceuticals | 1.69 Bn | 1.14 Bn | -3.82 Mn | 545.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 545.68 Mn |
| Mar 31, 2026 | 654.47 Mn |
| Dec 31, 2025 | 743.29 Mn |
| Sep 30, 2025 | 659.84 Mn |
| Jun 30, 2025 | 525.11 Mn |
| Mar 31, 2025 | 500.45 Mn |
| Dec 31, 2024 | 594.35 Mn |
| Sep 30, 2024 | 427.65 Mn |
| Jun 30, 2024 | 474.34 Mn |
| Mar 31, 2024 | 296.33 Mn |
| Dec 31, 2023 | 391.57 Mn |
| Sep 30, 2023 | 387.32 Mn |
| Jun 30, 2023 | 405.87 Mn |
| Mar 31, 2023 | 473.15 Mn |
| Dec 31, 2022 | 549.91 Mn |
| Sep 30, 2022 | 454.65 Mn |
| Jun 30, 2022 | 453.88 Mn |
| Mar 31, 2022 | 507.89 Mn |
| Dec 31, 2021 | 285.12 Mn |
| Sep 30, 2021 | 394.72 Mn |